Delhi thalassemia patients face a dire shortage of the essential injection Desferal, causing panic and desperation as ...

I would cautiously say that the mortality rate for newborns diagnosed with sickle cell at birth is decreasing.

The cumulative results of decades of work and advances in medicine are reflected in the increased survival of thalassaemia ...

The Cambridge company, which was the first gene editing company in the world to go public back in 2016, is dropping work on ...

The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.

The Cambridge biotech, the first gene editing company to go public eight years ago, is laying off 180 workers as it focuses ...

JonesResearch downgraded Editas Medicine (EDIT) to Hold from Buy with no price target after the company announced their decision to end the ...

When you give to Light Up A Lawn, Light Up A Life, you are supporting programs like Nationwide Children's cutting-edge gene ...

Chardan analyst Geulah Livshits downgraded Editas Medicine (EDIT) to Neutral from Buy and withdrew the firm’s price target after the company announced a strategic transition to focus entirely on ...

KeyBanc downgraded ServiceNow (NOW) to Sector Weight from Overweight. While the firm has been thrilled with ServiceNow all ...

Editas, which was unable to identify a development or licensing partner for reni-cel, is focusing its resources on its in vivo pipeline.

Shares of Agios Pharmaceuticals collapsed Monday on an unexpected side effect related to the company's thalassemia treatment, ...